Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
FOUNDAYO (ORFORGLIPRON CALCIUM) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
FOUNDAYO
NDA
Get alerts
ORFORGLIPRON CALCIUM | N220934 | ELI LILLY AND CO
6 strengths
1 unique patent
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
1 unique patent, 1 exclusivity by expiration date
All strengths
EQ 0.8MG BASE
EQ 2.5MG BASE
EQ 5.5MG BASE
EQ 9MG BASE
EQ 14.5MG BASE
EQ 17.2MG BASE
Active (1)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
Today
RE50455
Sep. 26, 2037
NCE
Apr. 1, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (6)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — EQ 0.8MG BASE
RLD
1 patent
1 exclusivity
▴
TABLET;ORAL | Approved: Apr 1, 2026
Patents (1)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
RE50455
Sep 26, 2037
—
Yes
Yes
U-4474
—
Exclusivities (1)
Code
Date
Status
NCE
Apr 1, 2031
Active
#002 — EQ 2.5MG BASE
RLD
1 patent
1 exclusivity
▾
TABLET;ORAL | Approved: Apr 1, 2026
#003 — EQ 5.5MG BASE
RLD
1 patent
1 exclusivity
▾
TABLET;ORAL | Approved: Apr 1, 2026
#004 — EQ 9MG BASE
RLD
1 patent
1 exclusivity
▾
TABLET;ORAL | Approved: Apr 1, 2026
#005 — EQ 14.5MG BASE
RLD
1 patent
1 exclusivity
▾
TABLET;ORAL | Approved: Apr 1, 2026
#006 — EQ 17.2MG BASE
RLD
1 patent
1 exclusivity
▾
TABLET;ORAL | Approved: Apr 1, 2026